Animal Model Market Size By Animal Type (Mice, Rats, Fish, Birds, Cattles, Pigs, Amphibians, Guinea Pigs, Dogs, Cats, Rabbits, Monkeys, Sheep, Hamsters), By Technology, Application, End-use, Organizations & Forecast, 2022 - 2028

Industry Trends

Animal Model Market size exceeded USD 17.7 billion in 2021 and is projected to grow at over 8.1% CAGR from 2022 to 2028 owing to the growing investments in R&D for innovations in drug discovery and development processes. Growing research and development activities in pharmaceutical and biotech industry coupled with increasing number of clinical trials is projected to fuel the industry share during the estimated timeframe.
 

To get more details on this report: Request Free Sample PDF
 

For instance, as per the U.S. Congressional Budget Office, in 2019, the pharmaceutical industry spent around USD 83 billion on research and development (R&D) activities in the U.S. The research activities across pharmaceutical & biotechnology companies have augmented tremendously, and have doubled over the recent years, with surging demand for personalized medicine. As a result, significant research activities and investments are set to promote the demand for animal model in research laboratories and biopharmaceutical companies.
 

An animal model is a living and non-human species that are primarily utilized for a more precise understanding of diseases comprising infectious & chronic ailments. These animal model aid in different drugs, treatments, and therapies developments processes in pharmaceutical companies, academic and research institutes, etc. It is the major means of an experiment for scientists to perform numerous research and development activities that can be unfeasible or ethically banned with humans. They are highly used to obtain data related to disease and its diagnosis, prevention, treatment.
 

However, strict regulations and guidelines related to the use of animal model in research studies may have a negative impact on animal model market growth. In the last few years, the employment of strict regulations and guidelines for animal protection and welfare in several nations has resulted in limiting research practices and bans on the use of animals for different study purposes. In 2021, the Members of the European Parliament demanded the European Union action plan to end the use of animals in research and testing. Further, numerous countries have taken initiatives to ban the use of animals in the cosmetic companies owing to rising concern over the use of animals in cosmetic testing.
 

The COVID-19 arose as an unprecedented public health concern across the globe and has positively impacted the animal model industry landscape. The significant demand for COVID-19 diagnosis, prevention, and treatment solutions has augmented in order to prevent infections due to coronavirus. The usage of animal model in COVID-19 research studies is rising at a significant pace for antiviral drug and vaccine development. As per the recent research article, non-human-primate models had been explored for coronavirus in rhesus macaques, cynomolgus macaques, and African green monkeys.
 

Further, K18-hACE2 transgenic mice were considered to be one of the best models for COVID-19. The demand for a large number of animal model increased at a rapid pace across the globe to ensure the safety & efficacy of new entities before going for human trials. The FDA had implemented several programs during the COVID-19 public health emergency to ensure continuous and timely accessibility of high-quality therapeutics to respond effectively. Thus, the adoption of these animal model in research facilities surged tremendously that closely mimics the clinical manifestation of SARS-CoV-2.
 

Several market players and government agencies emphasized the investment in R&D for the development of more suitable genetically engineered models. These significant initiatives were intended to ease the urgent need for the fast-track evaluation of potential drugs as well as the clinical trials of vaccines.
 

Increasing number of pharmaceutical research and development activities is set to propel the market statistics

Growing number of pharmaceutical research and development activities for the development of novel therapeutics is expected to drive the market growth. The growing number of R&D activities in the pharmaceutical companies contributed to the U.S. FDA approval of 355 novel medications from 2008 to 2019. The number of authorized medicines is significantly high and further rising, considering the fact that only 12% of drugs participating in the clinical trials are approved by the FDA.
 

This highlights the surging R&D activities in the biopharmaceutical space that are expected to increase in the near future. As per the WHO data, during 1999-2021, the U.S. had the highest total number of trials (157,618), followed by China (80,333) and Japan (57,754). In 2021, the U.S. and Germany led R&D funding followed by a high-income country for COVID-19 vaccine related research activities.
 

In 2021, COVAX, co-lead by the WHO committed the delivery of 870 million COVID-19 vaccine doses to support equitable access to vaccines across the globe. These statistics are expected to augment the demand for animal model as these models are crucial in ensuring safety and efficacy at various stages. Thus, R&D investments, surging clinical trial studies, and a growing number of research initiatives are anticipated to drive the industry scenario significantly over the forecast timeframe.
 

Clinical advantages offered by the mice animal model is expected to drive the preference for these animals

Based on animal type, the animal model market is segmented as mice, rats, fish, birds, cattles, pigs, amphibians, guinea pigs, dogs, cats, rabbits, monkeys, sheep, hamsters, and others. The mice segment was valued at over USD 8,974 million in 2021 owing to their genetic similarity to humans, increasing use in the study of human diseases, etc. The use of these mice model is significantly surging as mice and humans have around 99% of similarity in genotype. This is further augmenting the use of mice model in an extensive range of applications in cardiovascular, immunology, diabetes, and oncology studies among others.
 

The use of mice in pharmaceutical & biotechnology companies is growing to understand human diseases intending to discover and improvise therapeutics. Several academic and research Institutes are significantly incorporating mice models in the study of different diseases such as hypertension, Parkinson's disease, and atherosclerosis among others. Moreover, several genetically modified mice were used to model SARS-CoV-2 infection to define and develop effective preventions and treatments. Thus, the demand for unique inbred and mutant mice models is rapidly rising attributable to their similar genetic makeup to the human genome and facilitates large scale/high throughput research making it a cost-efficient model.
 

Availability of government & private funding and the adoption of CRISPR technology is expected to facilitate the business expansion

To get more details on this report: Request Free Sample PDF
 

Based on technology, the animal model market is segmented into CRISPR, microinjection, embryonic stem cell, injection, nuclear transfer, and others. The CRISPR segment was valued at more than USD 5,668 million in 2021 due to potential applications of these techniques in the correction of genetic defects, its simplicity & efficiency, and allows easy programming by changing the guide sequence among others.
 

The CRISPR-Cas9 is enabling the reduction in cost & time required for genome editing, thereby augmenting the production of research model with more extensive genetic modifications. Biomedical uses of genetically modified animal model are several that comprise understanding of gene function, understanding disease mechanisms or to aid drug development, etc.
 

Further, the recent advancements in this technology have stimulated the rapid and economically viable production of animal model in comparison to conventional gene-targeting methods. In 2020, Australian researchers in association with China scientists successfully used CRISPR-Cas9 to augment the advancement of pig research. Currently, the use of these technologies in the generation of transgenic animals is progressively expanding and showing benefits over the traditional techniques.
 

Surging demand for the development of novel therapeutics and personalized medicine is expected to spur the market forecasts

Based on application, the research & development segment held the largest market share in 2021 and is expected to reach over USD 17,872 million by 2028 owing to increasing demand for the development of novel therapeutics & personalized medications, growing R&D & clinical trials worldwide, etc. The rising awareness towards animal research is stimulating the demand for high standard models that is further set to prove conducive for segment growth.
 

Increasing demand for genetically modified models to meet the emerging needs in R&D activities is the key variable driving the utilization of animal model-based studies in research activities. Animal model-based research is crucial in research activities related to infectious disease, immunological diseases, etc. as it delivers a strong basis for analysing reasonable safety and efficacy.
 

This application comprises drug discovery, molecular biology, clinical research, and pharmaceutical development among others. Thus, a host of capabilities possessed by animal model-based research is projected to augment the use of these models in research and development activities.
 

Growing adoption of animal model in human diseases studies is expected to drive the market size

Based on use, animal model market is segmented into human and veterinary. The human segment was valued at more than USD 14,342.6 million in 2021 due to the surging consumption of personalized medicine, rising focus towards studying human-specific diseases, etc. The increasing prevalence of infectious and chronic diseases in the human population is stimulating the adoption of animal model in research laboratories and increasing research volume.
 

As per the World Health Organization data, around 41 million deaths are caused due to non-communicable diseases (NCDs) each year globally. These statistics are anticipated to augment the demand for genetically modified animals in the more precise understanding of human disease progression, disease pathogenesis, etc.
 

The humanized mouse models are considered as a powerful tool in understanding the origin & progress of human genetic disorders for identifying targets for therapeutic medications. Further, the animal model-based research is helping to make innovative discoveries, from novel COVID-19 vaccines & drugs to transplant procedures, anaesthetics, etc.
 

Clinical advantages offered by the animal model in pharmaceutical & biotechnology companies is expected to drive the preference for these models

To get more details on this report: Request Free Sample PDF
 

Based on end-use, animal model market is segmented into companies, organisations, academic and research institutes, and contract research organizations (CRO). The companies segment exceeded USD 10,922 million in 2021. This majority revenue share of the segment is attributed to a novel transformation in pharmaceutical & biotechnology companies, emergence of new technologies, the advent of cost-effective & more efficient approaches in research processes, and growing investment among others.
 

Continuous progress in the field of personalized medications has opened abundant possibilities to target different diseases and enabled the development of patient-centric models. This is expected to encourage the utilization of animal-based models in precision medicine research. Further, in the wake of COVID-19, numerous established pharmaceutical & biopharmaceutical firms have surged their R&D and manufacturing processes to develop diagnostic tests, vaccines, and medicines against the virus. The outbreak of coronavirus resulted in significant partnerships, collaborations, and agreements among companies to rapidly develop and commercialize vaccines against this infectious disease.
 

In Germany, between February 2020 and July 2021, around 61,389 animals were authorized for R&D projects related to SARS-CoV-2. As a result, the above-mentioned variables are expected to spur the animal model market in the coming years.
 

High number of ongoing R&D projects and access to advanced technologies in the North America region are projected to propel the regional business outlook

U.S. animal model market is anticipated to reach over USD 16,153 million by 2028 owing to the surging consumption of personalized medication, increasing rate of drug development, and rising healthcare expenditure in the U.S. among others. The development and market introduction of personalized medicine products is rapidly increasing in the U.S. attributed to different issues concerning the adverse effects of certain medicines. Moreover, the U.S. government initiatives involved in augmenting the adoption of personalized medicine in the country are boosting the significant demand for animal model-based research.
 

For instance, the U.S. government introduced the Precision Medicine Initiative to increase awareness related to cancer genetics & biology, innovate more effective medications for chronic ailments, and stimulate the use of precision medicine.
 

Significant investments offered by the National Institutes of Health (NIH) and the Defense Advanced Research Projects Agency (DARPA) is also contributing to an upsurge in R&D activities. The presence of well-established market players is leading to the increasing production and availability of humanized mice and rat models that will result in significant market growth.
 

Strategies implemented by major industry players are expected to generate business opportunities in the market

Some of the major market players operating in the animal model industry are Charles River, The Jackson Laboratory, Janvier Labs, Harbour BioMed, and genOway among others. Major players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum revenue share and promote company growth.
 

Recent industry developments:

• In February 2020, The Jackson Laboratory announced the availability of a specialized hACE2 genetically modified mice model to support COVID-19 research. This move offered new opportunities to develop novel transgenic mouse research models for optimum outcomes in biomedical research.
   
• In May 2018, Charles River announced the partnership agreement with genOway, a biotechnology firm that develops transgenic research models. This collaboration was intended to deliver access to 2000 Ready-to-Use Knockout Mice Models for in vivo research studies. This strategic collaboration helped the company to gain a competitive edge and bolster its industrial position.
   

Animal model market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments:

Click here to Buy Section of this Report

By Animal Type

• Mice
• Rats
• Fish
• Birds
• Cattles
• Pigs
• Amphibians
• Guinea Pigs
• Dogs
• Cats
• Rabbits
• Monkeys
• Sheep
• Hamsters
• Others

By Technology

• CRISPR
• Microinjection
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Others

By Application

• Research & Development 
  • Infectious Disease
  • Immunological Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Genetic Diseases
  • Neurological Diseases
  • Obesity
  • NAFLD/NASH
  • Renal disease
  • Diabetic eye disease
  • Fibrosis
  • Microbiome
  • Others
• Production and Quality Control
• Academics
• Preclinical Applications 
  • Infectious Disease
  • Immunological Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Genetic Diseases
  • Neurological Diseases
  • Obesity
  • NAFLD/NASH
  • Renal disease
  • Diabetic eye disease
  • Fibrosis
  • Microbiome
  • Others
• Others

By Use

• Human
• Veterinary

By End-use

• Companies 
  • Pharmaceutical
  • Biotechnology
  • Cosmetics
  • Others
• Organizations 
  • Government
  • Non-government
• Academic and Research Institutes
• Contract Research Organizations (CRO)

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Netherlands
  • Czech Republic
  • Poland
  • Belgium
  • Finland
  • Hungary
  • Denmark
  • Ireland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • Australia
  • South Korea
  • New Zealand
  • Taiwan
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel